Interim report Q1 2026

Strong start to the year with 7% organic sales growth and 37.8% adjusted EBITDA margin

Ester Baiget, President & CEO:” The year started strong with 7% organic sales growth against a high comparable. We delivered growth across all sales areas and in both Developed and Emerging markets, while achieving an adjusted EBITDA margin of 37.8%. Quarter after quarter, our results demonstrate the strength and resilience of our business model. We are confident in our full-year outlook and in our 2030 targets, including a 6–9% organic sales growth CAGR. As the world continues to change, the relevance and demand for biosolutions continue to grow. “

Please read the full announcement in PDF